A proximity-based therapeutics biotech developing targeted protein modulation medicines using proprietary PHICS and tPRIME platforms and PROTAC expertise
A proximity-based therapeutics biotech developing targeted protein modulation medicines using proprietary PHICS and tPRIME platforms and PROTAC expertise. Its pipeline targets autoimmune and inflammatory, oncology, and cardiometabolic diseases. Its lead program, PHT-776, is an oral IRAK4-targeted protein degrader in Phase I clinical evaluation.